Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago.
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand
Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients for its drug discovery and development services.
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
CRL Stock May Benefit From New Neuroscience Research Collaboration
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Charles River Laboratories: Changing Economics Reduces Compounding Ability (Rating Downgrade)
Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, suggesting there's no viable reinvestment opportunities to grow. The intrinsic worth of the business is $215–$223/share under present conditions, in my opinion, warranting a hold.
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
